Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital
References
- Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019 Aug;202(2):272–281.
- https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf. (date accessed: September 26, 2021).
- Hanna NH, Einhorn LH. Testicular cancer – discoveries and updates. N Engl J Med. 2014 Nov 20;371(21):2,005–16.
- Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European Association of Urology. guidelines on testicular cancer: 2015 update. Eur Urol. 2015 Dec;68(6):1,054–68.
- Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European Association of Urology. guidelines on testicular cancer: 2015 update. Eur Urol. 2015 Dec;68(6):1,054–68.
- Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018 Aug 1;29(8):1,658–1,686.
- Laguna M.P, Albers P. Albrech W, et al. EAU guidelines on testicular cancer. EAU; 2019. Available from: http://www.uroweb.org/guideline/testicular-cancer/. Accessed February 12, 2020.
- Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European Association of Urology. guidelines on testicular cancer: 2015 update. Eur Urol. 2015 Dec;68(6):1,054–68.
- Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, et al. interdisziplinäre Arbeitsgruppe Hodentumore. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie. 2011;34(1–2):59–64.
- Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, et al. International germ cell cancer classification update consortium. survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol. 2021 May 10;39(14):1,553–1,562. doi: <a href="https://doi.org/10.1200/JCO.20.03292." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.20.03292.</a> Epub 2021 Mar 17. PMID: 33729863; PMCID: PMC8099394.
- Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1,529–1,554.
- SEER cancer statistics factsheets: testicular cancer. National Cancer Institute. Bethesda, MD. 2019. date accessed: September 26, 2021.
- Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997 Jul 24;337(4):242–53.
- Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010 Jul 10;28(20):3,388–404.
- Jack RH, Davies EA, Møller H. Testis and prostate cancer incidence in ethnic groups in South East England. Int J Androl. 2007 Aug;30(4):215–20; discussion 220–1.
- Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer. 2005 Jul 10;115(5):822–7.
- Biggs ML, Schwartz SM. Differences in testis cancer survival by race and ethnicity: a population-based study, 1973–1999 (United States). Cancer Causes Control. 2004 Jun;15(5):437–44.
- Sadeghi M, Ghoncheh M, Mohammadian-Hafshejani A, Gandomani HS, Rafiemanesh H, Salehiniya H. Incidence and mortality of testicular cancer and relationships with development in Asia. Asian Pac J Cancer Prev. 2016;17(9):4,251–4,257.
- Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008 Feb 13;299(6):672–84. doi: <a href="https://doi.org/10.1001/jama.299.6.672." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1001/jama.299.6.672.</a> PMID: 18270356.
- Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1,435–40. doi: <a href="https://doi.org/10.1056/NEJM198706043162302." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJM198706043162302.</a> PMID: 2437455.
- de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001 Mar 15;19(6):1,629–40. doi: <a href="https://doi.org/10.1200/JCO.2001.19.6.1629." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2001.19.6.1629.</a> PMID: 11250991.
- Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, et al. Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007 May;18(5):917–24.
- Fankhauser CD, Sander S, Roth L, Beyer J, Hermanns T. Improved survival in metastatic germ-cell cancer. Ann Oncol. 2018 Feb 1;29(2):347–351.
- Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, et al. International Germ Cell Cancer Classification Update Consortium. predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol. 2021 May 10;39(14):1,563–1,574.
- Nguyen MM, Ellison LM. Testicular cancer patterns in Asian-American males: an opportunity for public health education to impact outcomes. Urology. 2005 Sep;66(3):606–9.
Language: English
Page range: 77 - 85
Submitted on: Nov 15, 2021
Accepted on: Dec 30, 2021
Published on: May 3, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Related subjects:
© 2022 Tanan Bejrananda, Komsan Leetanaporn, Nannapat Pruphetkaew, Monthira Tanthanuch, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.